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Abstract
Objective To assess the effectiveness and safety of melatonin in treating
severe sleep problems in children with neurodevelopmental disorders.
Design 12 week double masked randomised placebo controlled phase
III trial.
Setting 19 hospitals across England and Wales.
Participants 146 children aged 3 years to 15 years 8 months were
randomised. They had a range of neurological and developmental
disorders and a severe sleep problem that had not responded to a
standardised sleep behaviour advice booklet provided to parents four
to six weeks before randomisation. A sleep problem was defined as the
child not falling asleep within one hour of lights out or having less than
six hours’ continuous sleep.
Interventions Immediate release melatonin or matching placebo
capsules administered 45 minutes before the child’s bedtime for a period
of 12 weeks. All children started with a 0.5 mg capsule, which was
increased through 2 mg, 6 mg, and 12 mg depending on their response
to treatment.
Main outcome measures Total sleep time at night after 12 weeks
adjusted for baseline recorded in sleep diaries completed by the parent.
Secondary outcomes included sleep onset latency, assessments of child
behaviour, family functioning, and adverse events. Sleep was measured
with diaries and actigraphy.
Results Melatonin increased total sleep time by 22.4 minutes (95%
confidence interval 0.5 to 44.3 minutes) measured by sleep diaries
(n=110) and 13.3 (−15.5 to 42.2) measured by actigraphy (n=59).
Melatonin reduced sleep onset latency measured by sleep diaries (−37.5
minutes, −55.3 to −19.7 minutes) and actigraphy (−45.3 minutes, −68.8
to −21.9 minutes) and was most effective for children with the longest
sleep latency (P=0.009). Melatonin was associated with earlier waking
times than placebo (29.9 minutes, 13.6 to 46.3 minutes). Child behaviour
and family functioning outcomes showed some improvement and
favoured use of melatonin. Adverse events weremild and similar between
the two groups.
ConclusionsChildren gained little additional sleep onmelatonin; though
they fell asleep significantly faster, waking times became earlier. Child
behaviour and family functioning outcomes did not significantly improve.
Correspondence to: P Gringras Paul.Gringras@gstt.nhs.uk
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Melatonin was tolerable over this three month period. Comparisons with
slow releasemelatonin preparations or melatonin analogues are required.
Trial registration ISRCT No 05534585.
Introduction
Children with neurological and developmental disorders have
a higher prevalence of sleep disturbances than their unaffected
peers.1 Sleeping difficulties are often chronic and can result in
additional learning and behaviour problems,2 affect the whole
family’s health and wellbeing, and impair ability to continue in
employment or further education.3 Despite limited evidence of
the effectiveness of exogenous melatonin and some concerns
regarding safety, it is commonly prescribed to children with
neurodevelopmental delay, with wide variations in dose,4
because of its sleep phase shifting and hypnotic properties5 6.
Systematic reviews have looked at the effect of melatonin on
sleep parameters4 7-10 with recommendations that additional
randomised trials of melatonin be undertaken in children with
sleep disorders and neurodevelopmental disorders, autism, or
intellectual disability.4 7 8 We were commissioned to carry out
this study after successfully replying to a call from the Health
Technology Assessment Programme (part of the UK National
Institute of Health Research) to assess the use of melatonin in
children with impaired sleep and neurodevelopmental disorders.
Methods
Study design and oversight
This randomised, parallel group, double masked, multicentre,
placebo controlled, phase III trial was undertaken at 19 sites in
England and Wales. The trial was independently overseen by
an independent data safety monitoring committee and a trial
steering committee.
Study population
Children were eligible to participate if they were aged between
3 years and 15 years 8 months at registration visit, had a
neurodevelopmental disorder scoring 1.5 SD or more below the
mean on the adaptive behaviour assessment system (ABAS),11
and had a sleep disorder reported by parents for at least the past
five months characterised as failing to fall asleep within one
hour of “lights off” in three nights out of five or achieving less
than six hours of continuous sleep in three nights out of five,
or both. Children were required to be free from drugs that could
cause sleepiness and no have taken no melatonin within the
preceding five months. At registration, parents/carers were
provided with a booklet of advice on previously trialled and
standardised sleep behaviour treatment.12 This was used as a
run in to ensure that children who progressed to the
randomisation phase did not include those whose sleep disorder
could have been amenable to treatment with
non-pharmacological intervention. Sleep was monitored during
the registration period by using sleep diaries completed by
parents, and children were randomised if they continued to fulfil
the eligibility criteria with the sleep disorder criteria evident
from these sleep diaries.
Study intervention
The child’s age appropriate bedtime was established at the start
of the registration period and the trial drug was administered
45 minutes before this time either orally or through a feeding
tube if required. If the child was tube fed, the capsule was
opened and the study treatment suspended in an appropriate
medium.12 At randomisation, each child was given 0.5 mg. At
each of four weekly intervals, the child’s sleep pattern, as
recorded on the sleep diary, was reviewed and the dose was
increased to the next dose increment on the basis that the child
fulfilled the sleep disorder eligibility criteria, had received at
least five of the possible seven doses in the preceding week,
and had not experienced any serious adverse events. There was
a maximum of three dose increments from 0.5 mg, 2 mg, 6 mg,
and a maximum of 12 mg. Step down in dose was possible if
adverse effects were experienced at a higher dose. Participants
were followed up for 12 weeks from randomisation with a
combination of home visits, telephone calls, and clinic
attendance.
Randomisation
The trial statistician generated randomisation lists in Stata
(release 9, College Station, TX) in a 1:1 ratio using block
randomisation with random variable block lengths of two and
four stratified by centre. The statistician had no further access
until determination of the analysis population. The placebo
capsules and contents were identical in internal and external
appearance. Treatment packs were numbered sequentially and
dispensed by the pharmacy of each site. Treatment packs held
enough drugs for the 12 week period and allowed for potential
dose escalation. All trial staff and participants were blind to
treatment allocation throughout the trial.
Measuring sleep
The trial design included both subjective (diary) and objective
(actigraphy) measures of sleep, as recommended by Sadeh.13
There are benefits with each approach and reasons why the
results might not be concordant4 7; for example, sleep diaries
would not detect periods when the child was awake but not
disturbing the household (a particular concern for determining
sleep onset latency), and actigraphy could interpret restless sleep
as being awake. Between registration and study completion,
parents were asked to complete weekly sleep diaries.
The actigraph (MicroMini-Motionlogger, Ambulatory
Monitoring, New York), an accelerometer, is worn on the wrist
and movement is monitored continuously and stored within the
unit. Subsequent analysis of frequency and pattern of movement
by means of validated algorithms permits detection of basic
sleep-wake patterns.13Children wore the actigraph continuously
between registration and randomisation and the 12th week after
randomisation.
Study outcomes
The primary outcome was total sleep time, measured by diaries
completed by parents. Each night the minutes between the times
that the child went to sleep and woke up the next morning were
calculated minus any night time awakenings. A minimum of
five out of seven nights’ data at baseline (the week before
randomisation) and during the final week were required and the
weekly average calculated at each time point.
Secondary sleep outcomes included total sleep time measured
by actigraphy; sleep onset latency measured by diaries and
actigraphy; and sleep efficiency (the proportion of time spent
in bed asleep) measured by actigraphy. Sleep onset latency
measured the time taken for a child to go to sleep from “snuggle
down” time recorded on the sleep diary for both sleep diary and
actigraphy measures, with onset of sleep determined by the
respective methods.
Four questionnaires were completed at baseline and at the final
visit: the composite sleep disturbance index (CSDI; based on
allocating scores according to the frequency and duration of
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sleep problems reported by parents in questionnaires)14-16; the
aberrant behaviour checklist (ABC) to assess behavioural
problems17 18; the family impact module of the paediatric quality
of life inventory (PedsQL) to assess the quality of life of the
care giver19; and the Epworth sleepiness scale (ESS) to assess
the daytime sleepiness of the care giver.20We used a seven point
Likert scale to assess parental perception of child’s sleep quality.
We measured salivary melatonin concentrations for each
participant to calculate dim light melatonin onset (DLMO).
Melatonin is a hormone produced by the pineal gland in a
circadian rhythm influenced by light levels. Concentrations are
usually low during the day, but as evening approaches they start
to rise sharply peaking at around midnight. The beginning of
this rise is what is known as the dim light melatonin onset time.
Salivary samples were collected at two time points on the night
before the randomisation clinic visit and at the beginning of the
11th week with two nights of trial treatment omitted. Saliva
samples were collected hourly from 5 pm until the child’s usual
bedtime. A minimum of 2 ml of saliva was obtained by asking
the child to spit into a tube or by placing a saliva sponge in the
buccal cavity of the child’s mouth.
Saliva samples were also taken for DNA analysis to identify
genetic polymorphisms associated with the sleep outcomes.
DNA analyses are ongoing.
Safety assessments
Apaediatrician physically examined the children at the screening
and final visits. The frequency and severity of spontaneously
reported adverse events were recorded weekly along with
prompted reports of adverse events of interest (treatment
emergent signs and symptoms) covering somnolence, increased
excitability, mood swings, rash, hypothermia, and cough.
Weekly seizure diaries recording the type and number of seizures
were completed for those children with a pre-existing diagnosis
of epilepsy. The Investigator’s Brochure was referred to in the
assessment of causality and expectedness.
Exploratory analyses
Interactions between treatment and autism, the type of sleep
disorder (categorised as delayed sleep onset, poor sleep
maintenance, or both), baseline measurements, and child’s age
and weight were considered for the primary outcome and sleep
onset latency as post hoc analyses.
Additional analyses assessed whether there was a change in
morning wake up time and number and duration of night
awakenings to determine whether the observed increase in total
sleep time was explained by reduced sleep onset latency.
Statistical considerations
We used the “intention to treat” principle throughout and
undertook analyses with SAS (version 9.1.3, Cary, NC). Results
are presented with 95% confidence intervals. Continuous
outcomes are presented with means and standard deviations at
baseline, at study completion (week 12), and for the change
from baseline for each group. We used analysis of covariance
to adjust results for the dependent variables (total sleep time,
sleep onset latency) measured at baseline and in exploratory
analyses for treatment covariate interactions.
The trial was originally designed with two primary outcomes:
total sleep time according to the sleep diary and sleep onset
latency measured with actigraphy. During trial recruitment we
observed high rates of missing data (66%) for actigraphy so we
re-designated sleep onset latency as a secondary outcome and
removed the Bonferroni multiplicity adjustment21 in a protocol
amendment. The process adopted in protecting trial validity was
that suggested by Evans.22
Total sleep time was powered at 80% with a 5% significance
level to detect a change from baseline of one hour between the
melatonin and placebo group with a common standard deviation
of 1.7.23 24 Allowing for 20% missing data based on observed
rates at the time of the amendment, we calculated we needed
57 participants in each group.
We reassessed the estimate of the common standard deviation
used in the sample size calculation after the first 20 participants
as 1.2 (95% confidence interval 0.8 to 1.7), and the independent
data safety monitoring committee recommended the trial
continue without revision of the sample size calculation for the
estimated standard deviation used.
Results
The first participants were registered and randomised on 11
December 2007 and 28 January 2008, respectively, and the last
registered and randomised on 7May 2010 and 4 June 2010. All
children had intellectual/learning disability and included those
with epilepsies, autistic spectrum disorders, and a range of
genetic and chromosomal disorders. The CONSORT diagram
shows the screening, randomisation, and follow-up of the
patients ⇓. Baseline characteristics were similar between the
groups (table 1⇓).
The proportion of randomised participants who completed
follow-up was high at 94% (66/70) for melatonin and 92%
(70/76) for placebo. Proportions included within the primary
outcome analysis were 73% (51/70) for melatonin and 78%
(59/76) for placebo, largely because of the longitudinal data
required (minimum of five nights’ complete sleep diary). We
conducted a range of sensitivity analyses with regards to the
missing data. These sensitivity analyses, which included
reducing the number of nights’ sleep required to contribute to
the analysis and imputing worse/best recorded sleep parameters
to complete the sleep diaries, showed the robustness of
conclusions.
Dose escalation
Table 2⇓ shows that participants randomised to placebo titrated
more rapidly up to the maximum dose capsules. Twelve weeks
after randomisation only 19 (38%) participants receiving active
melatonin had escalated to themaximumdose (12mg) compared
with 49 (83%) receiving placebo. Nine children (18%) in the
active group remained taking the lowest dose (0.5mg) compared
with one child (2%) in the placebo group.
Sleep outcomes
Table 3⇓ provides results for primary and secondary sleep
outcomes. Melatonin increased total sleep time as measured
with sleep diaries (P=0.04), the primary outcome, but the
confidence interval excluded the 60 minute value determined
to be the minimum clinically relevant. The increase in total
sleep time was reduced as measured by actigraphy (P=0.36). A
range of prespecified sensitivity analyses showed the robustness
of conclusions to missing data.
Melatonin reduced sleep onset latency when measured by both
sleep diaries (P<0.001) and actigraphy (P<0.001). The size of
the improvement was larger whenmeasured by actigraphy (37.5
v 45.3minutes). Sleep efficiency did not improve withmelatonin
(P=0.09).
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Questionnaire outcomes
Table 4⇓ summarises the questionnaire outcomes. The composite
sleep disturbance index (CSDI) showed a significant reduction
favouring melatonin, indicating that parents thought the
frequency and duration of sleep problems had reduced after
treatment with melatonin. The Epworth sleepiness scale showed
a clinically small but statistically significant improvement of
1.6 points on the 24 point scale for melatonin compared with
placebo.
The results of the other measures tended to favour melatonin
but were not significant (table 5⇓).
Salivary melatonin
After randomisation, 67% (47/70) and 79% (60/76) of
participants on melatonin and placebo, respectively, provided
saliva samples for the calculation of dim light melatonin onset,
of which 15 and 12, respectively, were of insufficient volume
for analysis and the time of onset could not be ascertained for
25 (melatonin) and seven (placebo) participants. This difference
between the two groups was not detected before randomisation.
Where onset could not be calculated the reasons were possible
contamination (23 melatonin and three placebo); high baseline
concentrations (twomelatonin), and low volume (four placebo).
The limited data prevent meaningful analysis of the impact of
this phenomenon on treatment response.
Tolerability outcomes
Table 6 shows the number of participants experiencing any
treatment emergent sign or symptom (TESS)⇓. No formal
statistical tests were undertaken, and the results for each group
seemed similar. Seven serious adverse events were reported, of
which two (one in the placebo group and one in the melatonin
group) were considered related to the study drug in a blinded
assessment.
Sixteen children (eight in each group) had a diagnosis of
epilepsy before randomisation. Thirteen of these 16 children
experienced seizures in the period between randomisation and
the end of the study; none showed any deterioration in seizure
control or emergence of a new seizure type during this period.
No child developed seizures or a new diagnosis of epilepsy.
Exploratory analyses
Tables 7 and 8 show the results of exploratory analyses⇓⇓. The
treatment effect was not modified by the presence of autism
(P=0.85) or by the type of initial sleep disorder as reported by
care givers for total sleep time (P=0.56) or sleep onset latency
(autism P=0.56, sleep disorder P=0.43). Inclusion of age or
weight in the models did not improve the fit. The magnitude of
sleep onset latency as determined by baseline sleep diaries,
however, modified the treatment effect for sleep onset latency
such that melatonin had a greater effect in those with a greater
problem of getting to sleep (P=0.009); this was not evident for
total sleep time (P=0.19).
No differences were observed between groups for change in
average duration or frequency of night time awakenings.
Children woke 16.7 minutes earlier than at baseline after 12
weeks of treatment with melatonin, compared with children in
the placebo group who woke an average of 10.9 minutes later
than at baseline (table 7⇓). The comparison between groups was
significant (P<0.001), with children in the melatonin group
waking on average 29.9 minutes earlier than children in the
placebo group after adjustment for baseline (95% confidence
interval 13.6 to 46.3).
Discussion
In children with neurodevelopmental disorders and sleep
problems, immediate release melatonin was found to be more
effective than placebo in increasing total sleep time and reducing
sleep onset latency. In this randomised double masked placebo
controlled trial, adverse effects were few, mild in degree, and
distributed equally between the two groups with no increase in,
or new onset of, epileptic seizures. Total sleep time increased
by an average of 23 minutes and sleep onset latency reduced
by an average of 38 minutes.
Relation to other studies
Several systematic reviews have aimed to determine the effect
of melatonin on sleep parameters (table 9⇓). The inclusion
criteria of the systematic reviews vary as do the conclusions
regarding the effect of melatonin, from definitive absence of
effect10 to evidence of effect,8 and emphasising the need for
large confirmatory randomised controlled trials.4 7
The trials included within each meta-analysis were
heterogeneous in terms of populations of patients and the dose,
time, and durations of study treatments. Of methodological
concern are the number of small trials, suspicions of outcome
reporting bias25 within the trials,26 and the use of a crossover
design, the suitability of which has been questioned because of
the impact on the circadian timing system outlasting drug
washout periods.8 27
The impact of varying methods used to measure sleep, while
not considered to be of importance in Buscemi and colleagues,10
has been discussed by Rossignol and Frye7 and Philips and
Appleton.4 The differences in the methods used are evident in
the results of our study, particularly for total sleep time. The
difference could in part be attributed to night wakenings missed
by parents, though, as described by Philips and Appleton,4 the
relevance and clinical importance of changes in sleep pattern
that are not noted by parents and do not disrupt their own sleep
is debatable.
The effect estimate of melatonin on total sleep time in our study
is largely consistent with that reported by Buscemi and
colleagues,10 while the estimates reported by Rossignol and
Frye7 and Braam and colleagues8 in patients with intellectual
disability and autistic spectrum disorders extend to the upper
limit of our confidence interval. This is in contrast with a recent
open label dose escalation study of 24 children with autism,
which reported no improvement on total sleep time.28 Our
exploratory analysis did not identify autism as a modifier of
treatment effect, suggesting the differences in the size of effect
are not explained by differences in populations of patients.
The effect of melatonin on sleep onset latency was both
clinically and statistically significant based on both sleep diaries
and actigraphic measures. The minimum clinically relevant
difference defined a priori was 30 minutes and was held within
the confidence intervals for both sleep diaries and actigraphy.
This reduction is consistent with other reports of the use of
melatonin in typically developing children (35 minutes),29
children with intellectual disabilities (34 minutes),8 and children
with autism (39 minutes).7 In keeping with a recent study on
typically developing children we found that melatonin was most
effective for those children with the longest sleep latency.29 The
finding that our children receiving melatonin woke earlier than
controls by the end of the three month study is interesting and
has not been previously reported in children with
neurodevelopmental disorders. It is consistent with the effect
of melatonin in laboratory controlled studies30 and suggests that
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evening exogenous melatonin advances sleep phase over time
and therefore children fall asleep earlier but also wake earlier,
explaining the smaller effect on total sleep time.
Results for dim light melatonin onset were disappointing. If
samples are taken regularly for a 24 hour period the onset should
be measurable, whenever it occurs. For practical reasons,
however, it is common in paediatric populations to take five
swabs before bedtime. It is therefore possible to “miss” an onset
that precedes sampling or occurs when sampling has finished.
Some of the contamination and high baseline values in the
melatonin arm could reflect children who are poor metabolisers
and whose concentrations of exogenous melatonin had
accumulated during the study; however, it might also reflect
that the dose of melatonin was not actually omitted on the two
nights as required in the protocol.
Only low doses of melatonin are required to alter the sleep phase
in typically developing children, and, in this study, there was
support for starting treatment with a low dose of melatonin with
18% of children needing only 0.5 mgmelatonin. Although high
doses might usefully promote the sedative action of melatonin
in some children with neurodevelopmental disorders, this might
not be the case for slow metabolisers of melatonin.31
Measures of child behaviour and family quality of life tended
to favour melatonin but were not significant. There are several
possible explanations for this, including the possibility that our
measures were not sensitive enough over this time period. We
speculate that this might also be because of the relatively minor
effect melatonin had on total sleep time across this study.
Strengths and limitations
This was the first randomised controlled trial specifically
designed and powered to assess the impact of melatonin on total
sleep time over a three month period. We used subjective and
objective assessments of sleep and had a standardised parental
sleep behavioural intervention before treatment with melatonin
during which a routine bedtime was established. We also had
a systematic dose escalation protocol and included secondary
outcomes such as behavioural function and quality of life
measures. The study had a relatively long duration (one month
behavioural intervention and then three month drug trial) and
wide inclusion criteria across all children with
neurodevelopmental delay, maximising generalisability of results
to everyday clinical practice.
A limitation is the relatively high number of participants who
were either unable to tolerate actigraphy or in whom actigraphy
equipment failed. Unfortunately, the combination in many
children of both autistic spectrum disorders (in particular sensory
sensitivities) and severe learning difficulties meant that
actigraphy was often not well tolerated, and more watches were
broken or lost than expected. We have considerable previous
clinical and research experience using actigraphy, but few
studies have attempted to use actigraphy for this period of time
in this particular population. In a shorter open label study of
children with autism and normal intelligence, 25% of
actiwatches still needed to be used in alternative places.28
Although we decided not to use non-standard actigraphy
placements such as shoulder/waist for this study, this should be
an important consideration for future similar trials. Carers’
diaries, even for this prolonged period, were well received in
this study in contrast with other reports.7 32
Our 95% confidence intervals for total sleep time did not contain
the minimum clinically important difference of 60 minutes that
we defined before the study. Although this figure was reached
through consensus with experts and carers at the time, we
acknowledge the growing body of evidence suggesting that
smaller increase in total sleep time might be worthwhile over
cumulative nights.33 Our definition of a sleep disorder did not
vary across the age range of children included, potentially
meaning that younger children experienced greater deviation
from sleeping habit norms than older children, though
exploratory analyses found no effect of age or weight.
Our findings provide valuable evidence about the dosing,
tolerability, and effect of using melatonin in children with
neurodevelopmental and sleep disorders. They explain that
although (standard) immediate release melatonin significantly
reduces sleep onset latency, there is a more limited increase in
total sleep time that might arise as a result of increasingly early
waking time in the morning. Melatonin seemed tolerable in this
population of children with a range of neurological and
developmental disorders. We cannot comment on the efficacy
of slow release or combined preparations, which could be
important alternatives. Only head to head trials with other drugs,
including slow release melatonin and hypnotics/sedatives, will
help clinicians and families decide which is the safest and most
effective.
We thank the children and families who participated in this study. We
acknowledge the support of the National Institute for Health Research,
through the Medicines for Children Research Network (MCRN) and
local research networks. The study was included on the UK CRC
portfolio and supported by the UK Medicines for Children Research
Network (MCRN) and conducted through the MCRN clinical trials unit.
We also thank the independent trial steering committee (chaired by
Stuart Logan, Andy Vail, and Anthony McShane) and independent data
monitoring committee (chaired by Anthony Marson, David Jones, and
John Gibbs) and Sally Eagle for additional analyses. The trial supplies,
active drug and placebo, were manufactured by Penn Pharmaceuticals
for which costs were provided by Alliance Pharma, who had no other
involvement in the study.
Contributors: PG and RA were involved in the design of the study, the
funding application, development of the protocol, and recruitment of
patients as a local principal investigator, was co-chief investigator for
the trial and a member of the trial management group, and co-wrote
the paper. CG contributed to the design of the study and the funding
application, led the statistical team covering development of the data
collection tool, helped in data monitoring, co-wrote the statistical analysis
plan, was a member of the trial management group, and co-wrote the
paper. APJ was a member of the trial management group, cleaned and
analysed the data, co-wrote the statistical analysis plan, prepared the
monitoring reports and the final report, and commented on drafts of the
paper. LW contributed to the design of the study and the funding
application, advised on the use of actigraphy and outcomes reported
by patients, was a member of the trial management group, and
commented on drafts of the paper. PRW led the design of the trial, the
funding application, and development of the protocol, was a member
of the trial management group, and commented on drafts of the final
paper. AS was involved in the design of the protocol, the funding
application, recruitment of patients as a local principal investigator, was
a member of the trial management group, and provided comments on
the draft paper. PM contributed to the design of the study and the funding
application, advised on the use of actigraphy and outcomes reported
by patients, was a member of the trial management group, and
commented on drafts of the paper. WPW contributed to the design of
the trial and the funding application, organised and analysed pre-protocol
consumer involvement, helped to recruit patients as a local principal
investigator, and commented on a draft of the paper. IC, TA, and AE
were involved in the funding application, recruitment of patients as local
principal investigators, and provided comments on the draft paper. PG
is guarantor.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6664 doi: 10.1136/bmj.e6664 (Published 5 November 2012) Page 5 of 16
RESEARCH
What is already known on this topic
Sleep disorders are common in children with neurodevelopmental disorders
In these children, melatonin is widely prescribed at varying doses
Systematic reviews have had inconsistent conclusions
What this study adds
Children given melatonin fall asleep earlier, but after three months’ treatment also wake up earlier
The major effect of melatonin is on sleep latency, rather than total sleep time
Doses of melatonin as low as 0.5 mg can be effective
The presence of autism is not a significant moderator of treatment effect
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Tables
Table 1| Baseline characteristics of children with neurodevelopmental disorders in study of effect of melatonin on sleep problems
Placebo (n=76)Melatonin (n=70)Baseline characteristic
48 (63)49 (70)No (%) of boys
100.7 (37.4; 37-186)106 (34.8; 44-181)Mean (SD; range) age (months)
51.9 (11.3; 10-74)50.8 (9.9; 40-73)Mean (SD; range) ABAS-GAC score
No (%) by neurodevelopmental delay:
9 (12)13 (19)Developmental delay (DD) alone
5 (7)8 (11)DD and epilepsy
30 (39)30* (43)DD and autistic spectrum disorder (ASD)
3 (4)0DD, ASD, epilepsy
29 (38)19* (27)DD and “other”
No (%) by sleep disorder†:
29 (39.2)27 (40.3)Delayed sleep onset
16 (21.6)10 (14.9)Poor sleep maintenance
29 (39.2)30 (44.8)Poor sleep onset and maintenance
ABAS GAC=adaptive behaviour assessment system-general adaptive composite.
*One participant was re-classified from having DD and “other” to DD and ASD by independent assessment by PG and RA.
†Not classified for three participants receiving melatonin and two receiving placebo.
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Table 2| Dose escalation for participants included in primary outcome analysis of effect of melatonin on sleep problems in children with
neurodevelopmental disorders
No (%) receiving placebo (n=59)No (%) receiving melatonin (n=51*)
12 mg6 mg2 mg0.5 mg12 mg6 mg2 mg0.5 mg
Dose escalation phase
00059 (100)00051 (100)Baseline
0049 (83)10 (17)0032 (63)19 (37)Week 1
040 (68)15 (25)4 (7)023 (45)15 (29)13 (26)Week 2
31 (53)18 (31)9 (15)1 (2)18 (35)8 (16)15 (29)10 (20)Week 3
42 (71)12 (20)4 (7)1 (2)19 (37)10 (20)13 (26)9 (1)Week 4
Dose maintenance phase
43 (73)10 (17)5 (9)1 (2)19 (37)10 (20)13 (26)9 (18)Week 5
46 (78)9 (15)3 (5)1 (2)20 (39)10 (20)12 (24)9 (18)Week 6
50 (85)5 (9)3 (5)1 (2)20 (39)12 (24)11 (22)8 (16)Week 7
49 (83)6 (10)3 (5)1 (2)19 (38)12 (24)11 (22)8 (16)Week 8
49 (83)6 (10)3 (5)1 (2)20 (40)11 (22)11 (22)8 (16)Week 9
49 (83)5 (9)4 (7)1 (2)19 (38)12 (24)10 (20)9 (18)Week 10
49 (83)4 (7)5 (9)1 (2)19 (38)12 (24)10 (20)9 (18)Week 11
49 (83)5 (9)4 (7)1 (2)19 (38)12 (24)10 (20)9 (18)Week 12
*At each of weeks 8-12 one child was withdrawn, total=5.
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Table 3| Primary and secondary sleep outcomes in study of effect of melatonin on sleep problems in children with neurodevelopmental
disorders. Figures are means (SD)
Adjusted difference
PlaceboMelatonin
ChangeWeek 12Baseline
No of
childrenChangeWeek 12Baseline
No of
children
Sleep diary
22.4 (0.5 to 44.3)*12.5 (52.5)558.0 (68.9)545.5 (66.0)5940.5 (71.8)571.3 (72.0)530.8 (64.8)51Total sleep (min)
−37.5 (−55.3 to
−19.7)†
−9.7 (49.6)92.4 (63.0)102.1 (57.7)59−47.2 (64.4)54.8 (51.9)102.0 (72.6)54Sleep onset latency
(min)
Actigraphy
13.3 (−15.5 to 42.2)8.3 (52.0)420.6 (82.9)412.3 (83.2)2915.7 (63.6)449.9 (73.8)434.2 (72.3)30Total sleep (min)
−45.3 (−68.8 to
−21.9)†
−3.71 (47.4)104.1 (59.5)107.8 (54.9)25−58.3 (53.7)68.4 (41.0)126.8 (71.5)24Sleep onset latency
(min)
4.03 (−0.6 to 8.7)1.56 (9.5)64.83 (11.7)63.3 (12.3)284.8 (9.8)70.23 (11.3)65.4 (11.3)30Sleep efficiency‡
(%)
*P<0.05.
†P<0.001.
‡No of minutes spent sleeping in bed/total No of minutes spent in bed)×100.
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Table 4| Outcomes of questionnaires used to determine effect of melatonin on sleep problems in children with neurodevelopmental
disorders. Figures are mean (SD) scores
Adjusted
difference (95%
CI)
PlaceboMelatonin
ChangeWeek 12Baseline
No of
childrenChangeWeek 12Baseline
No of
children
−1.00 (−1.8 to
−0.2)*
−1.3 (2.2)5.8 (2.5)7.0 (2.1)65−2.4 (2.8)5.1 (2.9)7.5 (2.4)60CSDI scale 0-12
Aberrant behaviour checklist:
−1.0 (−3.1 to 1.2)−1.9 (6.7)13.6 (10.0)15.5 (10.3)68−3.1 (6.6)13.5 (10.1)16.6 (10.3)64Irritability, agitation,
crying (scale 0-45)
0.3 (−1.5 to 2.1)−2.8(6.0)8.0 (7.5)10.8 (8.8)67−3.1(6.2)9.3 (8.3)12.4 (9.6)60Lethargy, social
withdrawal (scale 0-48)
0.1(−0.9 to 1.2)−0.7 (3.4)4.3 (4.1)5.0 (4.8)69−1.0 (3.6)5.1 (4.5)6.1 (4.9)64Stereotypic behaviour
(scale 0-21)
−1.5 (−4.1 to 1.2)−3.0 (8.5)18.9 (11.2)21.9 (11.1)68−4.9 (7.7)18.6 (10.4)23.5 (9.9)64Hyperactivity, non-
compliance (scale
0-48)
−0.4 (−1.1 to 0.4)−0.6 (2.2)3.2 (3.2)3.7 (3.2)67−1.3 (2.7)3.5 (2.7)4.8 (3.2)64Inappropriate speech
(scale 0-12)
PedsQL family impact module:
3.5 (−1.6 to 8.7)1.3 (15.7)57.5 (20.6)56.2 (18.0)695.4 (14.7)58.7 (20.8)53.3 (17.5)64HRQoL (scale 0-100)
4.4 (−0.8 to 9.7)2.0 (14.6)52.1 (23.7)50.1 (22.8)696.4 (16.9)56.6 (23.6)50.2 (21.3)64Family functioning
(scale 0-100)
−1.6 (−2.9 to
−0.3)*
0.3 (3.8)7.1 (5.0)6.9 (5.3)66−1.3 (5.0)5.4 (4.5)6.7 (5.4)62ESS (scale 0-24)
CSDI=composite sleep disturbance index; PedsQL=paediatric quality of life inventory; HRQoL=health related quality of life; ESS=Epworth sleepiness scale.
*P<0.05
†Higher scores are worse for CSDI, ABC, and ESS, and lower scores are worse for PedsQL.
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Table 5| Global measure of parents’ perception of child’s sleep quality in study of effect of melatonin on sleep problems in children with
neurodevelopmental disorders. Figures are means (SD)
Adjusted difference (95% CI)
Placebo (n=55)Melatonin (n=52)
ChangeWeek 12BaselineChangeWeek 12Baseline
−5.9 (−17.8 to 6.1)−2.7 (36.9)31.0 (36.3)33.7 (35.3)−7.3 (35.5)24.0 (33.2)31.3 (34.3)Mean % of dissatisfied night sleeps
−0.2 (−0.7 to 0.2)−0.3 (1.4)3.7 (1.2)4.0 (1.3)−0.4 (1.4)3.4 (1.4)3.8 (1.2)Mean scores
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Table 6| Treatment emergent signs and symptoms (TESS) in study of effect of melatonin on sleep problems in children with
neurodevelopmental disorders
Placebo (n=76)Melatonin (n=70)
Event EventsNo (%) of childrenEventsNo (%) of children
Prompted adverse events report (TESS)
4228 (36.8)3622 (31.4)Coughing
2517 (22.4)3416 (22.9)Mood swings
3218 (23.7)2915 (21.4)Vomiting
1916 (21.1)2313 (18.6)Increased excitability
108 (10.5)1711 (15.7)Rash
1310 (13.2)149 (12.9)Somnolence
44 (5.3)86 (8.6)Hypothermia
139 (11.8)126 (8.6)Increased activity*
1311 (14.5)33 (4.3)Nausea*
65 (6.6)21 (1.4)Dizziness
11 (1.3)21 (1.4)Breathlessness*
00 (0)11 (1.4)Hung-over feeling*
00 (0)00 (0)Tremor*
11 (1.3)00 (0)Seizures
Unprompted adverse events spontaneously reported
108 (10.5)148 (11.4)Fatigue
147 (9.2)1210 (14.3)Headache
10740 (52.6)8231 (44.3)Other
*Originally included within TESS but removed in April 2009.
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Table 7| Frequency and duration of night time awakenings and wake up time in study of effect of melatonin on sleep problems in children
with neurodevelopmental disorders
Adjusted difference (95%
CI)
Placebo (n=59)Melatonin (n=51)
ChangeWeek 12BaselineChangeWeek 12Baseline
0.0 (−0.3 to 0.3)−0.1 (−0.3 to 0.1)0.6 (1.5)0.7 (1.6)−0.1 (−0.4 to 0.1)0.8 (1.2)0.9 (1.3)No of wakes
2.8 (−6.2 to 11.7)−1.3 (−8.6 to 6.0)9.7 (22.3)11.0 (17.4)−7.7 (−15.5 to 0.2)16.8 (26.3)24.5 (32.7)Total duration of nightly
wakes (min)
−29.9 (−46.3 to −13.6)*10.9 (−77.1 to 98.9)464.8 (57.3)453.9 (54.6)−16.7 (−103.3 to 70.0)426.4 (66.2)443.1 (59.1)Wake up time (min from
midnight)
*P<0.001.
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Table 8| Exploratory regression models in study of effect of melatonin on sleep problems in children with neurodevelopmental disorders.
Figures are estimates (95% confidence intervals)
Sleep onset latency (min)Total sleep time (min)
Autism
Model A (12 week mean=baseline mean+treatment group+autism):
43.5 (23.3 to 63.8)218.3 (125.3 to 11.3)Intercept
0.5 4 (0.4 to 0.6)0.6 (0.5 to 0.8)***Mean at baseline
−37.1 (−54.9 to −19.2)***22.8 (0.8 to 44.8 )*Treatment
−7.7 (−25.7 to 10.3)−6.9 (−28.9 to 15.2)Autism
Model B (12 week mean=baseline mean+treatment group+autism+treatment group×autism):
41.4 (19.7 to 63.0)218.7 (125.2 to 312.2)Intercept
0.5 (0.4 to 0.6)***0.6 (0.5 to 0.8)***Mean at baseline
−32.5 (−56.3 to −8.6)***21.0 (−8.1 to 50.1)*Treatment
−2.6 (−27.7 to 22.6)−8.8 (−39.3 to 21.6)**Autism
−10.5 (−46.6 to 25.6)−4.1 (−40.3 to 48.5)***Treatment×autism
Sleep disorder
Model A (12 week mean=baseline mean+treatment group+sleep disorder):
53.3 (28.7 to 77.9)212.9 (118.4 to 307.4)Intercept
0.5 (0.4 to 0.7)***0.6 (0.5 to 0.8)***Mean at baseline
−41.5 (−58.9 to −24.0)‡23.2 (0.6 to 45.7)*Treatment
−29.1 (−56.9 to −1.3)7.2 (−26.2 to 40.5)Sleep disorder (maintenance v onset)
−14.1 (−33.6 to 5.4)3.5 (−20.8 to 27.8)Sleep disorder (maintenance and onset v onset)
Model B (12 week mean=baseline mean+treatment group+sleep disorder category+treatment group×sleep disorder :
58.2 (32.1 to 84.4)208.8 (112.1 to 305.4)Intercept
0.5 (0.4 to 0.7)***0.6 (0.5 to 0.8)***Mean at baseline
−50.0 (−77.9 to −22.0)***30.5 (−5.6 to 66.5)Treatment
−43.1 (−78.0 to −8.2)12.1 (−30.6 to 54.8)Sleep disorder (maintenance v onset)
−17.5 (−43.8 to 8.8)9.2 (−24.5 to 42.9)Sleep disorder (maintenance and onset v onset)
35.3 (−17.9 to 88.5)−12.1 (−80.9 to 56.7)Treatment× Sleep disorder (maintenance v onset)
7.0 (−31.6 to 45.5)−12.1 (−61.1 to 36.9)Treatment× Sleep disorder (maintenance and onset v onset)
Baseline interaction
Model (12 week mean=baseline mean+treatment group+baseline mean×treatment group:
18.3 (−6.2 to 42.7)160.6 (36.7 to 284.6)Intercept
0.7 (0.5 to 0.9)***0.7 (0.5 to 1.0)***Mean at baseline
−0.4 (−33.1 to 32.4)143.1 (−38.2 to 324.6)Treatment
−0.4 (−0.6 to −0.9)**−0.2 (−0.6 to 0.1)Mean baseline×treatment
*P<0.05, **P<0.01, ***P<0.001.
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Table 9| Summary of findings from systematic reviews of melatonin v placebo to treat sleep disorders
Authors’ conclusions
Sleep onset latency (SOL)Total sleep time (TST)
Population Estimate (95% CI)
No of
children
No of
trialsEstimate (95%CI)
No of
children
No of
trials
No significant effect on
SOL and small and
clinically unimportant effect
on sleep efficiency
WMD: −13.2 (−27.3
to 0.9)
1636WMD: 15.6 (7.2 to
24.0)
3829Secondary sleep
disorders;
heterogeneous
population
Buscemi,10 12
trials, 7 crossover
Decreases sleep latency
and increases total sleep
time
WMD: −33.8
(−42.97 to −24.70)
2737WMD: 49.8 (34.2
to 64.8)
2577Intellectual disability,
adults and children
Braam,8 9 trials, 7
crossover
Improved sleep
parameters and minimal
side effects. Call for large
RCT
Hedge’s g: 2.46
(1.96 to 2.98);
Glass’s Δ: 1.28
(0.67 to 1.89)†
575Hedge’s g: 1.07
(0.49 to 1.65);
Glass’s Δ: 0.93
(0.33 to 1.53)*
55Autistic spectrum
disorders
Rossignol,7 5
controlled trials, 5
crossover, 57
patients
Might be effective in
reducing SOL. No
evidence of effect on TST.
Call for large RCT
No meta-analysisNo meta-analysisChildren with
neurodevelopmental
disabilities
Phillips,4 3 cross
over studies, 35
children
WMD=weighted mean difference.
*44 min longer TST with melatonin.
†39 min shorter SOL with melatonin.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6664 doi: 10.1136/bmj.e6664 (Published 5 November 2012) Page 15 of 16
RESEARCH
Figure
Screening, randomisation, and follow-up of children with neurodevelopmental disorders and sleep disorders allocated to
melatonin or placebo
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